CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Rifaximin

Last Updated: August 5, 2014
Result type: Reports
Project Number: SR0388
Product Line: Reimbursement Review

Generic Name: Rifaximin

Brand Name: Zaxine

Manufacturer: Salix Pharmaceuticals Inc.

Therapeutic Area: Hepatic encephalopathy

Indications: Encephalopathy, Hepatic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 16, 2015

Recommendation Type: List with criteria/condition